Irish Biotech Aerska Secures $39M for Brain Shuttle RNA Medicines
February 17, 2026, 3:37 am
Aerska, an Irish biotech firm, secured a $39 million Series A funding round. This significant investment will propel its proprietary brain shuttle technology. The platform targets challenging neurological diseases. It delivers RNA medicines across the blood-brain barrier. Conditions like genetically-driven Alzheimer's disease are primary focuses. This breakthrough approach aims to preserve cognitive function. It seeks to extend healthy lives for many patients. The funding accelerates clinical translation. It offers new hope in neurodegeneration treatment. This positions Aerska as a leader in innovative CNS therapeutics.
Irish biotechnology is making bold strides. Dublin-based Aerska leads this charge. The company recently closed a substantial Series A financing round. It secured $39 million (€32 million). This capital injection is a major boost. It fuels Aerska's pioneering efforts. The firm develops RNA medicines. These drugs target central nervous system (CNS) diseases.
The funding round was robust. EQT Dementia Fund and age1 co-led the investment. Iaso Ventures also participated. Existing investors provided continued support. This latest round brings Aerska's total funding to $60 million. The company had previously announced seed funding in 2025. Investor confidence in Aerska's vision is clear. Its innovative approach addresses critical unmet medical needs.
Neurological diseases present immense challenges. The blood-brain barrier (BBB) is a significant hurdle. It protects the brain. It also blocks most medicines. This barrier severely limits therapeutic options. RNA interference (RNAi) therapeutics show great promise. Yet, effective delivery to the brain remains difficult. Aerska aims to overcome this. Its technology directly confronts this historical problem.
Aerska's core innovation is its "brain shuttle" technology. This platform enables targeted drug delivery. It allows RNAi therapeutics to reach the CNS. The technology uses antibody-oligo conjugates (AOC). These AOCs are designed to cross the BBB efficiently. They deliver RNA medicines directly to brain tissue. This systemic administration marks a breakthrough. It promises uniform and deep brain distribution. It also achieves durable target gene knockdown.
The company's mission is profound. It seeks to preserve minds. It aims to protect memories. It envisions longer, healthier lives for patients. Aerska silences genes that cause harm. This strategy targets diseases at their source. Genetically-driven forms of Alzheimer's disease are a key focus. Other devastating brain disorders are also targets. The approach offers new hope.
The Series A proceeds have a clear purpose. They will advance Aerska's AOC platform. This platform is progressing toward clinical trials. The funding supports further research and development. It moves therapies closer to patients. This investment accelerates the journey from lab to clinic. It ensures continued development of cutting-edge RNA medicines.
Aerska's investment highlights a broader trend. European funding for neurological therapeutics is surging. Several companies received significant capital in 2025. These firms pursue genetic or molecular approaches. Belgium- and France-based Axoltis Pharma raised €18 million. It advances treatments for ALS, Alzheimer's, and Parkinson's. France-based EpilepsyGTX secured €28 million. It pushes gene therapies for severe epilepsy. The UK's TRIMTECH Therapeutics announced €28.6 million. This funds protein degrader therapies for neurodegenerative diseases.
Collectively, these rounds represent substantial investment. Approximately €90 million flowed into CNS programs in 2025. This underscores sustained investor interest. Platforms addressing neurological disease biology are attractive. Solutions for delivery challenges also draw attention. Aerska stands out as an Irish entrant in this robust funding cohort. Its unique brain shuttle technology positions it well.
Aerska's strategy focuses on upstream intervention. It targets the genetic forms of neurological disease. This approach transforms outcomes. It serves populations previously underserved. Current therapeutic approaches have limitations. Aerska offers a groundbreaking platform. It aims to fill critical gaps. It seeks to improve cognitive function. It strives to enhance quality of life.
The company strengthens its leadership. New members join Aerska's Board of Directors. Arno de Wilde, Managing Director at EQT, now serves on the board. Philip Scheltens, Partner and Head of the Dementia Fund at EQT Life Sciences, also joins. Alex Colville, General Partner at age1, completes the new appointments. These additions bring valuable expertise. They will guide Aerska's strategic direction.
Aerska operates from Dublin, Ireland. Its research operations extend to London, UK. This dual presence supports its global ambitions. It leverages scientific talent across regions. The company is committed to innovation. It pioneers new frontiers in neuropharmacology. The potential impact of its brain shuttle technology is immense. It could redefine treatment paradigms.
The investment reflects a shared commitment. It supports high-impact therapeutics. It addresses a significant unmet need. Neuroscience drug development is complex. Aerska’s work offers a beacon of hope. It promises transformative treatments. It targets devastating conditions. The future of neurological care may well involve these RNA medicines.
Aerska’s platform aims for broad brain distribution. It seeks durable target gene knockdown. This could unlock new therapeutic possibilities. Intravenous or subcutaneous administration is envisioned. This would simplify treatment regimens. It would improve patient access. The company's progress is closely watched. Its innovative solutions could change countless lives.
The fight against neurodegeneration is ongoing. Aerska provides a powerful new weapon. Its advanced RNAi therapies offer precision. They target the root causes of disease. This systematic approach is groundbreaking. It moves beyond symptomatic relief. It offers a path to truly transformative care. The global community eagerly anticipates its clinical advances.
Irish biotechnology is making bold strides. Dublin-based Aerska leads this charge. The company recently closed a substantial Series A financing round. It secured $39 million (€32 million). This capital injection is a major boost. It fuels Aerska's pioneering efforts. The firm develops RNA medicines. These drugs target central nervous system (CNS) diseases.
The funding round was robust. EQT Dementia Fund and age1 co-led the investment. Iaso Ventures also participated. Existing investors provided continued support. This latest round brings Aerska's total funding to $60 million. The company had previously announced seed funding in 2025. Investor confidence in Aerska's vision is clear. Its innovative approach addresses critical unmet medical needs.
Neurological diseases present immense challenges. The blood-brain barrier (BBB) is a significant hurdle. It protects the brain. It also blocks most medicines. This barrier severely limits therapeutic options. RNA interference (RNAi) therapeutics show great promise. Yet, effective delivery to the brain remains difficult. Aerska aims to overcome this. Its technology directly confronts this historical problem.
Aerska's core innovation is its "brain shuttle" technology. This platform enables targeted drug delivery. It allows RNAi therapeutics to reach the CNS. The technology uses antibody-oligo conjugates (AOC). These AOCs are designed to cross the BBB efficiently. They deliver RNA medicines directly to brain tissue. This systemic administration marks a breakthrough. It promises uniform and deep brain distribution. It also achieves durable target gene knockdown.
The company's mission is profound. It seeks to preserve minds. It aims to protect memories. It envisions longer, healthier lives for patients. Aerska silences genes that cause harm. This strategy targets diseases at their source. Genetically-driven forms of Alzheimer's disease are a key focus. Other devastating brain disorders are also targets. The approach offers new hope.
The Series A proceeds have a clear purpose. They will advance Aerska's AOC platform. This platform is progressing toward clinical trials. The funding supports further research and development. It moves therapies closer to patients. This investment accelerates the journey from lab to clinic. It ensures continued development of cutting-edge RNA medicines.
Aerska's investment highlights a broader trend. European funding for neurological therapeutics is surging. Several companies received significant capital in 2025. These firms pursue genetic or molecular approaches. Belgium- and France-based Axoltis Pharma raised €18 million. It advances treatments for ALS, Alzheimer's, and Parkinson's. France-based EpilepsyGTX secured €28 million. It pushes gene therapies for severe epilepsy. The UK's TRIMTECH Therapeutics announced €28.6 million. This funds protein degrader therapies for neurodegenerative diseases.
Collectively, these rounds represent substantial investment. Approximately €90 million flowed into CNS programs in 2025. This underscores sustained investor interest. Platforms addressing neurological disease biology are attractive. Solutions for delivery challenges also draw attention. Aerska stands out as an Irish entrant in this robust funding cohort. Its unique brain shuttle technology positions it well.
Aerska's strategy focuses on upstream intervention. It targets the genetic forms of neurological disease. This approach transforms outcomes. It serves populations previously underserved. Current therapeutic approaches have limitations. Aerska offers a groundbreaking platform. It aims to fill critical gaps. It seeks to improve cognitive function. It strives to enhance quality of life.
The company strengthens its leadership. New members join Aerska's Board of Directors. Arno de Wilde, Managing Director at EQT, now serves on the board. Philip Scheltens, Partner and Head of the Dementia Fund at EQT Life Sciences, also joins. Alex Colville, General Partner at age1, completes the new appointments. These additions bring valuable expertise. They will guide Aerska's strategic direction.
Aerska operates from Dublin, Ireland. Its research operations extend to London, UK. This dual presence supports its global ambitions. It leverages scientific talent across regions. The company is committed to innovation. It pioneers new frontiers in neuropharmacology. The potential impact of its brain shuttle technology is immense. It could redefine treatment paradigms.
The investment reflects a shared commitment. It supports high-impact therapeutics. It addresses a significant unmet need. Neuroscience drug development is complex. Aerska’s work offers a beacon of hope. It promises transformative treatments. It targets devastating conditions. The future of neurological care may well involve these RNA medicines.
Aerska’s platform aims for broad brain distribution. It seeks durable target gene knockdown. This could unlock new therapeutic possibilities. Intravenous or subcutaneous administration is envisioned. This would simplify treatment regimens. It would improve patient access. The company's progress is closely watched. Its innovative solutions could change countless lives.
The fight against neurodegeneration is ongoing. Aerska provides a powerful new weapon. Its advanced RNAi therapies offer precision. They target the root causes of disease. This systematic approach is groundbreaking. It moves beyond symptomatic relief. It offers a path to truly transformative care. The global community eagerly anticipates its clinical advances.